We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aquestive Therapeutics (AQST) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
The latest trading session saw Aquestive Therapeutics (AQST - Free Report) ending at $1.43, denoting a +1.42% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily gain of 0.73%. Elsewhere, the Dow saw an upswing of 0.62%, while the tech-heavy Nasdaq appreciated by 0.93%.
The specialty pharmaceutical company's shares have seen a decrease of 6% over the last month, not keeping up with the Medical sector's loss of 4.57% and the S&P 500's loss of 2.29%.
The investment community will be paying close attention to the earnings performance of Aquestive Therapeutics in its upcoming release. The company is predicted to post an EPS of -$0.11, indicating a 52.17% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $11.33 million, indicating a 1.13% decrease compared to the same quarter of the previous year.
AQST's full-year Zacks Consensus Estimates are calling for earnings of -$0.25 per share and revenue of $46.75 million. These results would represent year-over-year changes of +77.68% and -1.95%, respectively.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Aquestive Therapeutics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Aquestive Therapeutics currently has a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 97, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Aquestive Therapeutics (AQST) Beats Stock Market Upswing: What Investors Need to Know
The latest trading session saw Aquestive Therapeutics (AQST - Free Report) ending at $1.43, denoting a +1.42% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily gain of 0.73%. Elsewhere, the Dow saw an upswing of 0.62%, while the tech-heavy Nasdaq appreciated by 0.93%.
The specialty pharmaceutical company's shares have seen a decrease of 6% over the last month, not keeping up with the Medical sector's loss of 4.57% and the S&P 500's loss of 2.29%.
The investment community will be paying close attention to the earnings performance of Aquestive Therapeutics in its upcoming release. The company is predicted to post an EPS of -$0.11, indicating a 52.17% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $11.33 million, indicating a 1.13% decrease compared to the same quarter of the previous year.
AQST's full-year Zacks Consensus Estimates are calling for earnings of -$0.25 per share and revenue of $46.75 million. These results would represent year-over-year changes of +77.68% and -1.95%, respectively.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Aquestive Therapeutics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Aquestive Therapeutics currently has a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 97, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.